<?xml version="1.0" encoding="UTF-8"?>
<p>There were 233 596 continuous PPI users and 626 887 non–PPI users included in the study, after applying inclusion and exclusion criteria (
 <xref ref-type="fig" rid="zoi190614f3">Figure 3</xref>). Among the patients eligible for the study, 28.5% had at least 1 PPI dispensing event, and 2.9% were receiving continuous PPI therapy. The baseline characteristics of the included patients are summarized in 
 <xref rid="zoi190614t1" ref-type="table">Table 1</xref>. The median (interquartile range) age was 70 (61-80) years in the non–PPI users group (56.3% female) and 71 (62-81) years in the continuous PPI users group (55.8% female). Compared with non–PPI users, continuous PPI users were dispensed more treatments for cardiovascular diseases (80.6% vs 69.1%), diabetes (19.6% vs 14.7%), psychiatric diseases (50.0% vs 31.5%), and obstructive airway diseases (20.1% vs 11.4%).
</p>
